… We compared the baseline characteristics of patients in DAPA-HF with a number of recent
randomized controlled trials.18-21 Two of these had broad inclusion criteria and are shown in …

… In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), …
risk of worsening heart failure and death in patients with heart failure and reduced ejection …

… Patients who have HFrEF with or without type 2 diabetes and an … in DAPA-HF. We
calculated the incidence of the primary outcome (cardiovascular death or worsening heart failure) …

… Using study-level published data from DAPA-HF and patient-… heart failure events and renal
outcomes in all randomly assigned patients with HFrEF and in relevant subgroups from DAPA…

Objectives This study assessed the efficacy and safety of dapagliflozin in patients who were
or were not taking sacubitril/valsartan at baseline in the DAPA-HF (Study to Evaluate the …

… of health status using KCCQ in the DAPA-HF trial, we observed that treatment with … the
primary composite end point of cardiovascular death or worsening HF, and its components, to a …

… the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart
failure (HF) and death in patients with HF … was consistent in relation to background HF therapy. …

… failure (HF) in patients with heart failure and reduced ejection fraction (HFrEF). In this analysis
of DAPA-HF, … secondary end point of total failure hospitalizations (first and recurrent) and …

… planning a pooled analysis of DAPA-HF and DELIVER was to … on death from CV causes in
DAPA-HF (HR 0.82 (95% CI 0.69–… of DAPA-HF and DELIVER, the number of patients with HF …

… Our patient-level pooled analysis of DAPA-CKD and DAPA-HF … in patients with chronic
kidney disease and heart failure, in … disease and heart failure. This is particularly relevant in …